Page last updated: 2024-10-18

glycine and Amyloidosis

glycine has been researched along with Amyloidosis in 13 studies

Amyloidosis: A group of sporadic, familial and/or inherited, degenerative, and infectious disease processes, linked by the common theme of abnormal protein folding and deposition of AMYLOID. As the amyloid deposits enlarge they displace normal tissue structures, causing disruption of function. Various signs and symptoms depend on the location and size of the deposits.

Research Excerpts

ExcerptRelevanceReference
"Bortezomib, a proteasome inhibitor (PI), has shown efficacy in the treatment of newly diagnosed and relapsed light chain (AL) amyloidosis, and is often used in combination with cyclophosphamide and dexamethasone."9.51Phase 2 trial of ixazomib, cyclophosphamide, and dexamethasone for previously untreated light chain amyloidosis. ( Bergsagel, PL; Bradt, EE; Buadi, FK; Dingli, D; Dispenzieri, A; Fonder, A; Gertz, MA; Go, RS; Gonsalves, W; Hayman, SR; Helgeson, DK; Hobbs, M; Hwa, YL; Kapoor, P; Kourelis, TV; Kumar, SK; Lacy, MQ; LaPlant, BR; Larsen, JT; Leung, N; Muchtar, E; O'Brien, P; Rajkumar, SV; Siddiqui, M; Warsame, R, 2022)
"This phase 1/2 study assessed the safety, tolerability, and preliminary efficacy of the oral proteasome inhibitor (PI) ixazomib in patients with relapsed/refractory immunoglobulin light chain (AL) amyloidosis."9.24A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis. ( Berg, D; Cohen, AD; Comenzo, RL; Dispenzieri, A; Gupta, N; Hui, AM; Jaccard, A; Kukreti, V; Merlini, G; Palladini, G; Sanchorawala, V; Schönland, SO; Seldin, DC; Yang, H; Zonder, JA, 2017)
"Bortezomib, a proteasome inhibitor (PI), has shown efficacy in the treatment of newly diagnosed and relapsed light chain (AL) amyloidosis, and is often used in combination with cyclophosphamide and dexamethasone."5.51Phase 2 trial of ixazomib, cyclophosphamide, and dexamethasone for previously untreated light chain amyloidosis. ( Bergsagel, PL; Bradt, EE; Buadi, FK; Dingli, D; Dispenzieri, A; Fonder, A; Gertz, MA; Go, RS; Gonsalves, W; Hayman, SR; Helgeson, DK; Hobbs, M; Hwa, YL; Kapoor, P; Kourelis, TV; Kumar, SK; Lacy, MQ; LaPlant, BR; Larsen, JT; Leung, N; Muchtar, E; O'Brien, P; Rajkumar, SV; Siddiqui, M; Warsame, R, 2022)
"This phase 1/2 study assessed the safety, tolerability, and preliminary efficacy of the oral proteasome inhibitor (PI) ixazomib in patients with relapsed/refractory immunoglobulin light chain (AL) amyloidosis."5.24A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis. ( Berg, D; Cohen, AD; Comenzo, RL; Dispenzieri, A; Gupta, N; Hui, AM; Jaccard, A; Kukreti, V; Merlini, G; Palladini, G; Sanchorawala, V; Schönland, SO; Seldin, DC; Yang, H; Zonder, JA, 2017)
" A kindred has been identified in which a glycine to arginine mutation at residue 26 in apoA-I is associated with hypoalphalipoproteinemia and hereditary systemic amyloidosis."3.68In vivo metabolism of a mutant apolipoprotein, apoA-IIowa, associated with hypoalphalipoproteinemia and hereditary systemic amyloidosis. ( Benson, MD; Brewer, HB; Gregg, RE; Meng, MS; Rader, DJ; Schaefer, JR; Zech, LA, 1992)
"The association of multiple endocrine neoplasia type 2A with the dermatological disorder cutaneous lichen amyloidosis has already been reported, and mutations in the Cys634 have been identified in different families."1.30A Cys634Gly substitution of the RET proto-oncogene in a family with recurrence of multiple endocrine neoplasia type 2A and cutaneous lichen amyloidosis. ( Betsos, N; Camera, G; Celli, I; Claudiani, F; Romeo, G; Seri, M, 1997)

Research

Studies (13)

TimeframeStudies, this research(%)All Research%
pre-19902 (15.38)18.7374
1990's4 (30.77)18.2507
2000's3 (23.08)29.6817
2010's2 (15.38)24.3611
2020's2 (15.38)2.80

Authors

AuthorsStudies
Muchtar, E1
Gertz, MA1
LaPlant, BR1
Buadi, FK1
Leung, N1
O'Brien, P1
Bergsagel, PL1
Fonder, A1
Hwa, YL1
Hobbs, M1
Helgeson, DK1
Bradt, EE1
Gonsalves, W1
Lacy, MQ1
Kapoor, P1
Siddiqui, M1
Larsen, JT1
Warsame, R1
Hayman, SR1
Go, RS1
Dingli, D1
Kourelis, TV1
Dispenzieri, A2
Rajkumar, SV1
Kumar, SK1
Xing, Y1
Andrikopoulos, N1
Zhang, Z1
Sun, Y1
Ke, PC1
Ding, F1
Sanchorawala, V1
Palladini, G1
Kukreti, V1
Zonder, JA1
Cohen, AD1
Seldin, DC1
Jaccard, A1
Schönland, SO1
Berg, D1
Yang, H1
Gupta, N1
Hui, AM1
Comenzo, RL1
Merlini, G1
Maya-Martinez, R1
Gil-Rodriguez, P1
Amero, C1
Yazaki, M1
Varga, J1
Dyck, PJ1
Benson, MD2
De Carolis, P1
Galeotti, M1
Ficarra, G1
Masetti, M1
Grimaldi, D1
Cortelli, P1
Jacobson, DR1
Alves, IL1
Saraiva, MJ1
Thibodeau, SN1
Buxbaum, JN1
Dudek, SM1
Johnson, GV1
Seri, M1
Celli, I1
Betsos, N1
Claudiani, F1
Camera, G1
Romeo, G1
Akar, E1
Yalcinkaya, F1
Akar, N1
Bosseckert, H1
Rader, DJ1
Gregg, RE1
Meng, MS1
Schaefer, JR1
Zech, LA1
Brewer, HB1
Zuckerberg, A1
Gazith, J1
Rimon, A1
Reshef, T1
Gafni, J1

Clinical Trials (3)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Phase 1/2 Trial of Ixazomib in Combination With Cyclophosphamide and Dexamethasone in Patients With Previously Untreated Symptomatic Multiple Myeloma or Light Chain Amyloidosis[NCT01864018]Phase 1/Phase 287 participants (Actual)Interventional2013-08-20Active, not recruiting
A Phase 3, Randomized, Controlled, Open-label, Multicenter, Safety and Efficacy Study of Dexamethasone Plus MLN9708 or Physicians Choice of Treatment Administered to Patients With Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis[NCT01659658]Phase 3177 participants (Actual)Interventional2012-12-12Terminated (stopped due to Sponsor's decision)
An Open-Label, Dose-Escalation, Phase 1 Study of the Oral Formulation of MLN9708 Administered Weekly in Adult Patients With Relapsed or Refractory Light-Chain (AL) Amyloidosis Who Require Further Treatment[NCT01318902]Phase 127 participants (Actual)Interventional2011-04-27Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Maximum Tolerated (MTD) Dose of Cyclophosphamide (Phase I)

Will be defined as the dose level below the lowest dose that induces dose-limiting toxicity in at least 1/3 of patients, as assessed by National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0. (NCT01864018)
Timeframe: At 28 days

Interventionmg/m² weekly (Number)
Treatment (Ixazomib Citrate, Cyclophosphamide, Dexamethasone)400

Number of Patients Experiencing a Grade 3 or Greater Adverse Event at Least Possibly Related to Treatment as Assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0

The maximum grade for each type of adverse event will be recorded for each patient, and frequency tables will be reviewed to determine patterns. Additionally, the relationship of the adverse event(s) to the study treatment will be taken into consideration. Adverse events will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0. A grade 3 event is one that is severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care ADL. (NCT01864018)
Timeframe: Up to 5 years

InterventionParticipants (Count of Participants)
Phase I/II, Cohort A36
Phase II, Cohort B16

Percentage of Patients With Complete Response or Very Good Partial Response (Phase II, Cohort A)

The percentage of successes will be estimated by the number of successes divided by the total number of evaluable patients. Exact binomial 95% confidence intervals for the true success proportion will be calculated. (NCT01864018)
Timeframe: Up to 48 weeks

Interventionpercentage of participants (Number)
Treatment (Ixazomib Citrate, Cyclophosphamide, Dexamethasone)35

Progression-free Survival (PFS)

The distribution of PFS will be estimated using the method of Kaplan Meier. (NCT01864018)
Timeframe: Time from registration to the earliest date of documentation of disease progression or death due to any cause, assessed up to 5 years

Interventionmonths (Median)
Phase I/II, Cohort ANA
Phase II, Cohort BNA

Rate of Complete Response, Very Good Partial Response, or Partial Response (Phase II, Cohort B)

The proportion of successes will be estimated by the number of successes divided by the total number of evaluable patients. Exact binomial 95% confidence intervals for the true success proportion will be calculated. (NCT01864018)
Timeframe: Up to 48 weeks

Interventionpercentage of participants (Number)
Treatment (Ixazomib Citrate, Cyclophosphamide, Dexamethasone)63

Survival Time

The distribution of survival time will be estimated using the method of Kaplan-Meier. (NCT01864018)
Timeframe: Time from registration to death due to any cause, assessed up to 5 years

Interventionmonths (Median)
Phase I/II, Cohort ANA
Phase II, Cohort BNA

Maximum Tolerated (MTD) Dose of Cyclophosphamide With Ixazomib and Dexamethasone (Phase I)

Will be defined as the dose level below the lowest dose that induces dose-limiting toxicity in at least 1/3 of patients, as assessed by National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0. (NCT01864018)
Timeframe: At 28 days

Interventionmg weekly (Number)
MTD of ixazomibMTD of dexamethasone
Treatment (Ixazomib Citrate, Cyclophosphamide, Dexamethasone)440

2-Year Vital Organ (Heart or Kidney) Deterioration and Mortality Rate

Cardiac (Heart) deterioration was defined as the need for hospitalization for heart failure. Kidney deterioration was defined as progression to end-stage renal disease (ESRD) with the need for maintenance dialysis or renal transplantation. Vital organ deterioration was evaluated by an adjudication committee. Percentages were rounded off to the nearest decimal. As prespecified in the protocol, data was planned to be collected and analyzed in a combined way for non-ixazomib arm groups in this outcome measure. (NCT01659658)
Timeframe: Up to 2 years

Interventionpercentage of participants (Number)
Arm A: Ixazomib + Dexamethasone47
Arm B: Dexamethasone + Melphalan/Cyclophosphamide/Thalidomide/Lenalidomide54

Change From Baseline in 36-item Short Form General Health Survey (SF-36) Mental Component Summary Score at Week 28 of the PFS Follow-up

SF-36 Version 2 is a multipurpose, participant completed, short-form health survey with 36 questions that consists of an 8-scale profile of functional health and well-being scores as well as psychometrically-based physical and mental health summary measures. Physical component summary (PCS) is mostly contributed by physical function (PF), role physical (RP), bodily pain (BP), and general health (GH). Mental component summary (MCS) is mostly contributed by mental health (MH), role emotional (RE), social function (SF), and vitality (VT). Each component on the SF-36 item health survey is scored from 0 (best) to 100 (worst). Total score ranges from 0-100, where higher scores are associated with less disability and better quality of life. As prespecified in the protocol, data was planned to be collected and analyzed in a combined way for non-ixazomib arm groups in this outcome measure. (NCT01659658)
Timeframe: Baseline, Week 28 of the PFS Follow-up

Interventionscore on a scale (Mean)
Arm B: Dexamethasone + Melphalan/Cyclophosphamide/Thalidomide/Lenalidomide2.0

Change From Baseline in Amyloidosis Symptom Scale Total Score at Week 28 of the PFS Follow-up

The amyloidosis symptom scale questionnaire is a participant completed questionnaire that evaluates symptom severity of 3 symptoms: Swelling, Shortness of Breath and Dizziness, each rated on an 11-point scale where: 0=no symptoms to 10=very severe symptoms. Higher scores indicate worsening of symptoms. Total Score is the sum of all responses from the amyloidosis symptom scale ranging from 0 to 30. Higher scores represent higher levels of symptomatology or problems and a negative change from baseline indicates improvement. As prespecified in the protocol, data was planned to be collected and analyzed in a combined way for non-ixazomib arm groups in this outcome measure. (NCT01659658)
Timeframe: Baseline, Week 28 of the PFS Follow-up

Interventionscore on a scale (Mean)
Arm B: Dexamethasone + Melphalan/Cyclophosphamide/Thalidomide/Lenalidomide-16.0

Change From Baseline in Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (FACT/GOG-Ntx) Score at Week 28 of the PFS Follow-up

The FACT/GOG-Ntx is a participant completed questionnaire that comprises 11 individual items evaluating symptoms of neurotoxicity on a 5-point scale where: 0=not at all (best) to 4=very much for a total possible score of 0 to 44. Symptom scores are inverted so that higher scores of FACT/GOG-Ntx indicate higher quality of life or functioning. As prespecified in the protocol, data was planned to be collected and analyzed in a combined way for non-ixazomib arm groups in this outcome measure. (NCT01659658)
Timeframe: Baseline, Week 28 of the PFS Follow-up

Interventionscore on a scale (Mean)
Arm B: Dexamethasone + Melphalan/Cyclophosphamide/Thalidomide/Lenalidomide0.0

Change From Baseline in SF-36 Physical Component Summary Score at Week 28 of the PFS Follow-up

SF-36 Version 2 is a multipurpose, participant completed, short-form health survey with 36 questions that consists of an 8-scale profile of functional health and well-being scores as well as psychometrically-based physical and mental health summary measures. Physical component summary (PCS) is mostly contributed by physical function (PF), role physical (RP), bodily pain (BP), and general health (GH). Mental component summary (MCS) is mostly contributed by mental health (MH), role emotional (RE), social function (SF), and vitality (VT). Each component on the SF-36 item health survey is scored from 0 (best) to 100 (worst). Total score ranges from 0-100, where higher scores are associated with less disability and better quality of life. As prespecified in the protocol, data was planned to be collected and analyzed in a combined way for non-ixazomib arm groups in this outcome measure. (NCT01659658)
Timeframe: Baseline, Week 28 of the PFS Follow-up

Interventionscore on a scale (Mean)
Arm B: Dexamethasone + Melphalan/Cyclophosphamide/Thalidomide/Lenalidomide10.3

Duration of Hematologic Response

Duration of hematologic response (DOR) was defined as the time from the date of first documentation of a hematologic response to the date of first documented hematologic disease progression as determined by the investigator. As prespecified in the protocol, data was planned to be collected and analyzed in a combined way for non-ixazomib arm groups in this outcome measure. (NCT01659658)
Timeframe: From time of first documented response to disease progression (up to 115 months)

Interventionmonths (Median)
Arm A: Ixazomib + DexamethasoneNA
Arm B: Dexamethasone + Melphalan/Cyclophosphamide/Thalidomide/Lenalidomide21.19

EuroQol 5-Dimension 3-Level (EQ-5D-3L) Visual Analogue Scale Score

The EQ visual analogue scale (VAS) records the participant's self-rated health on a 20 centimeter vertical VAS that ranges from 0 (worst imaginable health state) to 100 (best imaginable health state). Baseline is defined as the value collected at the time closest to, but prior to, the start of study drug administration. As prespecified in the protocol, data was planned to be collected and analyzed in a combined way for non-ixazomib arm groups in this outcome measure. (NCT01659658)
Timeframe: At Week 28 of the OS follow-up

Interventionscore on a scale (Mean)
Arm B: Dexamethasone + Melphalan/Cyclophosphamide/Thalidomide/Lenalidomide23.0

Hematologic Disease Progression Free Survival

Hematologic disease PFS was defined as the time from the date of randomization to the date of first documentation of hematologic PD according to central laboratory results and ISA criteria as evaluated by an adjudication committee, or death due to any cause, whichever occurred first. As prespecified in the protocol, data was planned to be collected and analyzed in a combined way for non-ixazomib arm groups in this outcome measure. (NCT01659658)
Timeframe: From first dose of study drug until discontinuation of study drug due to disease progression or unacceptable toxicity, or death whichever occurs first (up to 115 months)

Interventionmonths (Median)
Arm A: Ixazomib + Dexamethasone29.50
Arm B: Dexamethasone + Melphalan/Cyclophosphamide/Thalidomide/Lenalidomide27.73

Number of Hospitalizations

A hospitalization was defined as at least one overnight stay in an intensive care unit and/or non-intensive care unit. If a single hospitalization included both an intensive care unit stay and a non-intensive care unit stay, the hospitalization was counted only once (as an intensive care unit stay). The mean number of hospitalizations is reported in this outcome measure. As prespecified in the protocol, data was planned to be collected and analyzed in a combined way for non-ixazomib arm groups in this outcome measure. (NCT01659658)
Timeframe: From first dose of study drug until discontinuation of study drug due to disease progression or unacceptable toxicity, or death whichever occurs first (up to 115 months)

Interventionhospitalizations (Mean)
Arm A: Ixazomib + Dexamethasone1.8
Arm B: Dexamethasone + Melphalan/Cyclophosphamide/Thalidomide/Lenalidomide1.4

Number of Participants With Serious Adverse Events (SAEs)

A SAE was defined as any untoward medical occurrence that at any dose resulted in death, was life-threatening, required inpatient hospitalization or prolongation of an existing hospitalization, resulted in persistent or significant disability or incapacity, was a congenital anomaly/birth defect or medically important event. (NCT01659658)
Timeframe: From first dose of study drug through 30 days after administration of the last dose of study drug (up to 115 months)

InterventionParticipants (Count of Participants)
Arm A: Ixazomib + Dexamethasone44
Arm B: Dexamethasone + Melphalan11
Arm B: Dexamethasone + Cyclophosphamide2
Arm B: Dexamethasone + Thalidomide0
Arm B: Dexamethasone + Lenalidomide17

Overall Survival

Overall survival was defined as the time from the date of randomization to the date of death. As prespecified in the protocol, data was planned to be collected and analyzed in a combined way for non-ixazomib arm groups in this outcome measure. (NCT01659658)
Timeframe: From first dose of study drug until discontinuation of study drug due to disease progression or unacceptable toxicity, or death whichever occurs first (up to 115 months)

Interventionmonths (Median)
Arm A: Ixazomib + Dexamethasone69.55
Arm B: Dexamethasone + Melphalan/Cyclophosphamide/Thalidomide/Lenalidomide43.17

Percentage of Participants With Best Vital Organ (Cardiac and/or Kidney) Response

Vital organ (heart and kidney) response rate was defined as the percentage of participants who achieved vital organ response according to central laboratory results and ISA criteria as evaluated by an adjudication committee. A vital organ response was defined as response of 1 or 2 of the involved vital organs with no change from Baseline in the rest of involved vital organs. Percentages were rounded off to the nearest decimal. As prespecified in the protocol, data was planned to be collected and analyzed in a combined way for non-ixazomib arm groups in this outcome measure. (NCT01659658)
Timeframe: From first dose of study drug until discontinuation of study drug due to disease progression or unacceptable toxicity, or death whichever occurs first (up to 115 months)

Interventionpercentage of participants (Number)
Arm A: Ixazomib + Dexamethasone19
Arm B: Dexamethasone + Melphalan/Cyclophosphamide/Thalidomide/Lenalidomide12

Percentage of Participants With Complete Hematologic Response

Complete hematologic response was defined as the percentage of participants with CR based on central laboratory results and the 2010 ISA Consensus Criteria as assessed by the investigator. CR: Complete disappearance of M-protein from serum and urine on immunofixation, and normalization of FLC ratio. Percentages were rounded off to the nearest decimal. As prespecified in the protocol, data was planned to be collected and analyzed in a combined way for non-ixazomib arm groups in this outcome measure. (NCT01659658)
Timeframe: From first dose of study drug until discontinuation of study drug due to disease progression or unacceptable toxicity, or death whichever occurs first (up to 115 months)

Interventionpercentage of participants (Number)
Arm A: Ixazomib + Dexamethasone30
Arm B: Dexamethasone + Melphalan/Cyclophosphamide/Thalidomide/Lenalidomide17

Percentage of Participants With Overall Hematologic Response

Overall hematologic response was defined as the percentage of participants with complete response (CR), very good partial response (VGPR) and partial response (PR) based on central laboratory results and the 2010 International Society of Amyloidosis (ISA) Consensus Criteria as assessed by an adjudication committee. CR: Complete disappearance of M-protein from serum and urine on immunofixation, and normalization of free light chain (FLC) ratio. VGPR: differential free light chain (difference between involved and uninvolved FLC levels; dFLC) < 40 mg/L. PR: ≥50% reduction in dFLC. Percentages were rounded off to the nearest decimal. (NCT01659658)
Timeframe: From first dose of study drug until discontinuation of study drug due to disease progression or unacceptable toxicity, or death whichever occurs first (up to 115 months)

Interventionpercentage of participants (Number)
Arm A: Ixazomib + Dexamethasone53
Arm B: Dexamethasone + Melphalan58
Arm B: Dexamethasone + Cyclophosphamide30
Arm B: Dexamethasone + Thalidomide50
Arm B: Dexamethasone + Lenalidomide51

Progression Free Survival (PFS)

PFS was defined as the time from the date of randomization to the date of first documentation of hematologic disease progression, or organ (cardiac or renal) progression, or death due to any cause, whichever occurred first according to central laboratory results and ISA criteria as evaluated by the investigator. As prespecified in the protocol, data was planned to be collected and analyzed in a combined way for non-ixazomib arm groups in this outcome measure. (NCT01659658)
Timeframe: From first dose of study drug until discontinuation of study drug due to disease progression or unacceptable toxicity, or death whichever occurs first (up to 115 months)

Interventionmonths (Median)
Arm A: Ixazomib + Dexamethasone11.86
Arm B: Dexamethasone + Melphalan/Cyclophosphamide/Thalidomide/Lenalidomide7.62

Time To Subsequent Anticancer Treatment

Time to subsequent anticancer therapy was defined as the time from randomization to the first date of subsequent anticancer therapy. Participants without subsequent anticancer therapy were censored at the date of death or last known to be alive. As prespecified in the protocol, data was planned to be collected and analyzed in a combined way for non-ixazomib arm groups in this outcome measure. (NCT01659658)
Timeframe: From first dose of study drug until subsequent anticancer treatment (up to 115 months)

Interventionmonths (Median)
Arm A: Ixazomib + Dexamethasone26.48
Arm B: Dexamethasone + Melphalan/Cyclophosphamide/Thalidomide/Lenalidomide12.45

Time To Treatment Failure (TTF)

TTF was defined as the time from randomization to the date of first documented treatment failure. Treatment failure was defined as: 1) death due to any cause; 2) hematologic progression or major organ progression according to central laboratory results and ISA criteria as evaluated by the investigator; 3) clinically morbid organ disease requiring additional therapy; or 4) withdrawn for any reason. As prespecified in the protocol, data was planned to be collected and analyzed in a combined way for non-ixazomib arm groups in this outcome measure. (NCT01659658)
Timeframe: From first dose of study drug until discontinuation of study drug due to disease progression or unacceptable toxicity, or death whichever occurs first (up to 115 months)

Interventionmonths (Median)
Arm A: Ixazomib + Dexamethasone10.32
Arm B: Dexamethasone + Melphalan/Cyclophosphamide/Thalidomide/Lenalidomide5.32

Time to Vital Organ (Heart or Kidney) Deterioration and Mortality Rate

Time to vital organ deterioration or death was assessed by the investigator and defined as the time from randomization to vital organ (heart or kidney) deterioration or death, whichever occurs first. Cardiac deterioration is defined as the need for hospitalization for heart failure. Kidney deterioration is defined as progression to ESRD with the need for maintenance dialysis or renal transplantation. As prespecified in the protocol, data was planned to be collected and analyzed in a combined way for non-ixazomib arm groups in this outcome measure. (NCT01659658)
Timeframe: From randomization to time of vital organ deterioration or death (up to 115 months)

Interventionmonths (Median)
Arm A: Ixazomib + Dexamethasone38.67
Arm B: Dexamethasone + Melphalan/Cyclophosphamide/Thalidomide/Lenalidomide26.09

Vital Organ Progression Free Survival

Vital organ PFS is defined as the time from the date of randomization to the date of first documentation of progression of vital organ (heart or kidney) according to central laboratory results and ISA criteria as evaluated by an adjudication committee, or death due to any cause, whichever occurs first. As prespecified in the protocol, data was planned to be collected and analyzed in a combined way for non-ixazomib arm groups in this outcome measure. (NCT01659658)
Timeframe: From first dose of study drug until discontinuation of study drug due to disease progression or unacceptable toxicity, or death whichever occurs first (up to 115 months)

Interventionmonths (Median)
Arm A: Ixazomib + Dexamethasone15.77
Arm B: Dexamethasone + Melphalan/Cyclophosphamide/Thalidomide/Lenalidomide11.01

Number of Participants in Each Category of the EuroQol 5-Dimensional (EQ-5D) Questionnaire Score

The European Quality of Life (EuroQOL) 5-Dimensional (EQ-5D) is a patient completed questionnaire consisting of 2 pages: the EQ-5D descriptive system and the EQ visual analogue scale (EQ VAS). The descriptive system comprises 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression). Each dimension has 3 possible choices: no problems to extreme problems. Higher scores=worsening of the quality of life. As prespecified in the protocol, data was planned to be collected and analyzed in a combined way for non-ixazomib arm groups in this outcome measure. (NCT01659658)
Timeframe: At Week 28 of the OS follow-up

,
InterventionParticipants (Count of Participants)
Mobility: No Problems in Walking AboutMobility: Some Problem in Walking AboutMobility: Confined to BedSelf-Care: No Problems With Self- CareSelf-Care: Some Problems Washing or DressingSelf-Care: Unable to Wash or DressUsual Activities: No Problems With Performing Usual ActivitiesUsual Activities: Some Problem With Performing Usual ActivitiesUsual Activities: Unable to Performing Usual ActivitiesPain/Discomfort: No Pain or DiscomfortPain/Discomfort: Moderate Pain or DiscomfortPain/Discomfort: Extreme Pain or DiscomfortAnxiety/Depression: Not Anxious or DepressedAnxiety/Depression: Moderately Anxious or DepressedAnxiety/Depression: Extremely Anxious or Depressed
Arm A: Ixazomib + Dexamethasone000000000000000
Arm B: Dexamethasone + Melphalan/Cyclophosphamide/Thalidomide/Lenalidomide010010010010001

Plasma Concentration of Ixazomib

As prespecified in the protocol, data for this outcome measure was planned to be collected for ixazomib arm group only. (NCT01659658)
Timeframe: Cycle 1, Day 1: 1, 4 hours postdose, Day 14: 144 hours postdose; Cycle 2, Day 1: predose, Day 14: 144 hours postdose; Cycles 3 to 10, Day 1: predose (cycle length=28 days)

Interventionnanogram per milliliter (ng/mL) (Geometric Mean)
Cycle 1 Day 1: 1 Hour Post-doseCycle 1 Day 14: 4 Hours Post-doseCycle 1 Day 14: 144 Hours Post-doseCycle 2 Day 1: Pre-doseCycle 2 Day 14: 144 Hours Post-doseCycle 3 Day 1: Pre-doseCycle 4 Day 1 Pre-doseCycle 5 Day 1 Pre-doseCycle 6 Day 1: Pre-doseCycle 7 Day 1: Pre-doseCycle 8 Day 1: Pre-doseCycle 9 Day 1: Pre-doseCycle 10 Day 1: Pre-dose
Arm A: Ixazomib + Dexamethasone16.51810.6523.8752.0004.7262.1872.2762.2642.2352.2992.0382.1432.232

Duration of Hematologic Response

Duration of hematologic response, measured as the time from the date of first documentation of a hematologic response to the date of hematologic disease progression. (NCT01318902)
Timeframe: From the date of first documentation of a hematologic response to the date of hematologic disease progression (Up to approximately 12 months)

Interventionmonths (Median)
Dose Escalation Cohort: Ixazomib 4.0 mg12.9
Dose Expansion Cohort: Ixazomib 4.0 mg (PI Naive)69.5
Dose Expansion Cohort: Ixazomib 4.0 mg (PI Exposed)19.7

Duration of Organ Response

Duration of organ response, measured as the time from the date of first documentation of a organ response to the date of organ disease progression. (NCT01318902)
Timeframe: From the date of first documentation of a organ response to the date of organ disease progression (Up to approximately 12 months)

Interventionmonths (Median)
Dose Escalation Cohort: Ixazomib 4.0 mg4.1
Dose Expansion Cohort: Ixazomib 4.0 mg (PI Naive)20.5
Dose Expansion Cohort: Ixazomib 4.0 mg (PI Exposed)18.25

Hematologic Disease Progression-Free Survival (PFS)

Hematologic disease PFS, measured as the time from the date of the first dose of ixazomib to the date of hematologic disease progression or death. (NCT01318902)
Timeframe: From the date of the first dose of ixazomib to the date of hematologic disease progression or death (Up to approximately 12 months)

Interventionmonths (Median)
Dose Escalation Cohort: Ixazomib 4.0 mg14.8
Dose Escalation Cohort: Ixazomib 5.5 mg7.2
Dose Expansion Cohort: Ixazomib 4.0 mg (PI Naive)73.0
Dose Expansion Cohort: Ixazomib 4.0 mg (PI Exposed)8.3

Maximum Tolerated Dose (MTD) of Ixazomib

MTD was highest dose of Ixazomib, at which <=1 of 6 participants experienced dose-limiting toxicity (DLT). DLT was defined using National Cancer Institute Common Terminology Criteria for Adverse Events, v 4.03 as: Grade 4 neutropenia (absolute neutrophil count <500 cells/mm^3) for >7 days;Grade 3 neutropenia with fever or infection;Grade 4 thrombocytopenia (platelets < 25,000/mm^3) for >7 days;Grade 3 thrombocytopenia with clinically significant bleeding;platelet count <10,000/mm^3;Grade 2 peripheral neuropathy with pain or >=Grade 3 peripheral neuropathy; >=Grade 3 nausea/emesis, diarrhea controlled by supportive therapy;Grade 3 QTc prolongation (QTc >500 msec);any >=Grade 3 nonhematologic toxicity except Grade 3 arthralgia/myalgia;or <1 week Grade 3 fatigue;delay in initiation of the subsequent therapy cycle by >2 weeks;other >=Grade 2 study drug-related nonhematologic toxicities requiring therapy discontinuation, considered possibly related to therapy as assessed by Investigator. (NCT01318902)
Timeframe: Cycle 1 (28 days)

Interventionmg (Number)
Dose Escalation Cohort: Ixazomib 4.0 mg4
Dose Escalation Cohort: Ixazomib 5.5 mg4

Number of Participants With Best Hematologic Response to Treatment Based on Investigators Assessment

The overall hematologic response rate is defined as number of participants with complete response (CR) or partial response (PR) or very good partial response (VGPR) as assessed by the investigator. Response is determined according to standardized criteria using a central laboratory. CR=serum and urine negative for monoclonal protein by immunofixation; or free light chain ratio normal; < 5% plasma cells in bone marrow without clonal dominance. PR=reduction in dFLC > 50%. VGPR= dFLC < 40 mg/L. (NCT01318902)
Timeframe: Day 22 to 28 in each cycle and end of treatment visit; then every 6 weeks thereafter until disease progression or initiation of subsequent antineoplastic therapy (Up to approximately 12 months)

InterventionParticipants (Count of Participants)
Dose Escalation Cohort: Ixazomib 4.0 mg4
Dose Escalation Cohort: Ixazomib 5.5 mg0
Dose Expansion Cohort: Ixazomib 4.0 mg (PI Naive)4
Dose Expansion Cohort: Ixazomib 4.0 mg (PI Exposed)3

Number of Participants With Best Organ Response to Treatment Based on Investigators Assessment

Organ response rate was estimated as the number of participants with documented organ response (ie. Heart or kidney ). Treatment response of amyloid-related organs were identified based on national cancer institute, common terminology criteria for adverse events (NCI CTCAE) Version 4.02 criteria. (NCT01318902)
Timeframe: At Cycles 3, 6, 9, and 12; every 6 months thereafter until disease progression or the initiation of subsequent antineoplastic therapy and at end of treatment (EOT) visit (Up to approximately 12 months)

InterventionParticipants (Count of Participants)
Dose Escalation Cohort: Ixazomib 4.0 mg2
Dose Escalation Cohort: Ixazomib 5.5 mg0
Dose Expansion Cohort: Ixazomib 4.0 mg (PI Naive)2
Dose Expansion Cohort: Ixazomib 4.0 mg (PI Exposed)2

Organ Disease Progression-Free Survival (PFS)

Organ disease PFS, measured as the time from the date of the first dose of ixazomib to the date of organ disease progression or death. (NCT01318902)
Timeframe: From the date of the first dose of ixazomib to the date of organ disease progression or death (Up to approximately 12 months)

Interventionmonths (Median)
Dose Escalation Cohort: Ixazomib 4.0 mgNA
Dose Escalation Cohort: Ixazomib 5.5 mgNA
Dose Expansion Cohort: Ixazomib 4.0 mg (PI Naive)NA
Dose Expansion Cohort: Ixazomib 4.0 mg (PI Exposed)NA

Percentage of Participants With One Year Hematologic Disease PFS

One-year survival, defined as the patient survival probability at 1 year after the date of first dose of ixazomib. (NCT01318902)
Timeframe: From the date of the first dose of ixazomib to the date of hematologic disease progression or death (Up to 1 year)

Interventionpercentage of participants (Number)
Dose Escalation Cohort: Ixazomib 4.0 mg83.3
Dose Expansion Cohort: Ixazomib 4.0 mg (PI Naive)80.0
Dose Expansion Cohort: Ixazomib 4.0 mg (PI Exposed)21.5

Recommended Phase 2 Dose (RP2D) of Ixazomib

The RP2D is the maximum tolerated dose (MTD) or less. The MTD is defined as the dose range at which ≤ 1 of 6 evaluable participants experience dose limiting toxicities (DLT) within the first 28 days of treatment (end of Cycle 1). The RP2D of Ixazomib was determined in dose escalation group on the basis of the totality of safety, tolerability, pharmacokinetics (PK) and pharmacodynamic (PD) data observed in Cycle 1. (NCT01318902)
Timeframe: Cycle 1 (28 days)

Interventionmg (Number)
Dose Escalation Cohort: Ixazomib 4.0 mg4
Dose Escalation Cohort: Ixazomib 5.5 mg4

Time to First Hematologic Response

Time to first hematologic response, measured as the time from the first dose of ixazomib to the date of first documentation of a hematologic response. (NCT01318902)
Timeframe: From the date of the first dose of ixazomib to the date of first documentation of a hematologic response (Up to approximately 12 months)

Interventionmonths (Median)
Dose Escalation Cohort: Ixazomib 4.0 mg0.79
Dose Expansion Cohort: Ixazomib 4.0 mg (PI Naive)3.45
Dose Expansion Cohort: Ixazomib 4.0 mg (PI Exposed)2.11

Time to First Organ Response

Time to first organ response, measured as the time from the first dose of ixazomib to the date of first documentation of a organ response. (NCT01318902)
Timeframe: From the date of the first dose of ixazomib to the date of first documentation of a organ response (Up to approximately 12 months)

Interventionmonths (Median)
Dose Escalation Cohort: Ixazomib 4.0 mg6.85
Dose Expansion Cohort: Ixazomib 4.0 mg (PI Naive)9.55
Dose Expansion Cohort: Ixazomib 4.0 mg (PI Exposed)6.85

Time to Hematologic Disease Progression

Time to hematologic progression, measured as the time from the date of the first dose of ixazomib to the date of first documented hematologic disease progression. (NCT01318902)
Timeframe: From the date of the first dose of ixazomib to the date of first documented hematologic disease progression (Up to approximately 12 months)

Interventionmonths (Median)
Dose Escalation Cohort: Ixazomib 4.0 mg14.8
Dose Escalation Cohort: Ixazomib 5.5 mgNA
Dose Expansion Cohort: Ixazomib 4.0 mg (PI Naive)73.0
Dose Expansion Cohort: Ixazomib 4.0 mg (PI Exposed)8.3

Time to Organ Disease Progression

Time to organ disease progression, measured as the time from the date of the first dose of ixazomib to the date of first documented organ disease progression. (NCT01318902)
Timeframe: From the date of the first dose of ixazomib to the date of first documented organ disease progression (Up to approximately 12 months)

Interventionmonths (Median)
Dose Escalation Cohort: Ixazomib 4.0 mg11
Dose Expansion Cohort: Ixazomib 4.0 mg (PI Naive)12.85
Dose Expansion Cohort: Ixazomib 4.0 mg (PI Exposed)25.15

AUC0-168: Area Under the Plasma Concentration-time Curve From Time 0 to 168 Hours Post-dose for Ixazomib

(NCT01318902)
Timeframe: Cycle 1: Day 1 (MTD cohort participants only, 4.0 mg) and Day 15 (all participants enrolled in the study): predose (within 1 hour (hr) before dosing), and postdose at multiple timepoints up to 168 hr

Interventionhr*ng/mL (Mean)
Cycle 1, Day 15
Ixazomib 5.5 mg1725.0

AUC0-168: Area Under the Plasma Concentration-time Curve From Time 0 to 168 Hours Post-dose for Ixazomib

(NCT01318902)
Timeframe: Cycle 1: Day 1 (MTD cohort participants only, 4.0 mg) and Day 15 (all participants enrolled in the study): predose (within 1 hour (hr) before dosing), and postdose at multiple timepoints up to 168 hr

Interventionhr*ng/mL (Mean)
Cycle 1, Day 1Cycle 1, Day 15
Ixazomib 4.0 mg861.01078.1

AUE0-168: Area Under Effect Curve of Whole Blood 20S Proteasome Inhibition From Zero to Concentration at 168 Hours for Ixazomib

(NCT01318902)
Timeframe: Cycle 1: Day 1 (MTD cohort participants only, 4.0 mg) and Day 15 (all participants enrolled in the study): predose (within 1 hour (hr) before dosing), and postdose at multiple timepoints up to 168 hr

Interventionhr*percentage of inhibition (Mean)
Cycle 1, Day 1Cycle 1, Day 15
Ixazomib 4.0 mg3333.63943.0

Cmax: Maximum Observed Plasma Concentration for Ixazomib

(NCT01318902)
Timeframe: Cycle 1: Day 1 (MTD cohort participants only, 4.0 mg) and Day 15 (all participants enrolled in the study): predose (within 1 hour (hr) before dosing), and postdose at multiple timepoints up to 168 hr

Interventionng/mL (Mean)
Cycle 1, Day 15
Ixazomib 5.5 mg92.20

Cmax: Maximum Observed Plasma Concentration for Ixazomib

(NCT01318902)
Timeframe: Cycle 1: Day 1 (MTD cohort participants only, 4.0 mg) and Day 15 (all participants enrolled in the study): predose (within 1 hour (hr) before dosing), and postdose at multiple timepoints up to 168 hr

Interventionng/mL (Mean)
Cycle 1, Day 1Cycle 1, Day 15
Ixazomib 4.0 mg54.0051.26

Ctrough: Plasma Concentration Immediately Prior to Dosing for Ixazomib

(NCT01318902)
Timeframe: Cycle 1: Day 1 (MTD cohort participants only, 4.0 mg) and Day 15 (all participants enrolled in the study): predose (within 1 hour (hr) before dosing), and postdose at multiple timepoints up to 168 hr

Interventionng/mL (Mean)
Cycle 1, Day 15
Ixazomib 5.5 mg5.3300

Ctrough: Plasma Concentration Immediately Prior to Dosing for Ixazomib

(NCT01318902)
Timeframe: Cycle 1: Day 1 (MTD cohort participants only, 4.0 mg) and Day 15 (all participants enrolled in the study): predose (within 1 hour (hr) before dosing), and postdose at multiple timepoints up to 168 hr

Interventionng/mL (Mean)
Cycle 1, Day 1Cycle 1, Day 15
Ixazomib 4.0 mg2.15392.9140

Emax: Maximum Observed Percent Inhibition of Whole Blood 20S Proteasome

(NCT01318902)
Timeframe: Cycle 1: Day 1 (MTD cohort participants only, 4.0 mg) and Day 15 (all participants enrolled in the study): predose (within 1 hour (hr) before dosing), and postdose at multiple timepoints up to 168 hr

Interventionpercentage of inhibition (Mean)
Cycle 1, Day 1Cycle 1, Day 15
Ixazomib 4.0 mg54.1061.09

Number of Participants With at Least One Treatment Emergent Adverse Event (TEAE) and Serious Adverse Event (SAE)

An AE is any untoward medical occurrence in a participant administered a medicinal investigational drug. The untoward medical occurrence does not necessarily have to have a causal relationship with treatment. An SAE is any untoward medical occurrence that results in death; is life-threatening; requires inpatient hospitalization or prolongation of present hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect or is a medically important event that may not be immediately life-threatening or result in death or hospitalization, but may jeopardize the participant or may require intervention to prevent one of other outcomes listed in definition above, or involves suspected transmission via a medicinal product of an infectious agent. A TEAE is defined as an AE that occurs after administration of first dose of study drug and through 30 days after last dose of study drug or until start of subsequent antineoplastic therapy. (NCT01318902)
Timeframe: From the first dose of study drug plus 30 days after last dose of study drug or until the initiation of subsequent antineoplastic therapy (Up to approximately 13 months)

,,,
InterventionParticipants (Count of Participants)
TEAESAE
Dose Escalation Cohort: Ixazomib 4.0 mg63
Dose Escalation Cohort: Ixazomib 5.5 mg55
Dose Expansion Cohort: Ixazomib 4.0 mg (PI Exposed)105
Dose Expansion Cohort: Ixazomib 4.0 mg (PI Naive)55

Number of Participants With Clinically Significant Abnormal Laboratory Values Reported as TEAE

The number of participants with any clinically significant abnormal standard safety laboratory values collected throughout the study reported as TEAEs. Parameters assessed were hematology, serum chemistry and urinalysis. Abnormal laboratory values were assessed as an AE if that value leads to discontinuation or delay in treatment, dose modification, therapeutic intervention, or is considered by the investigator to be a clinically significant change from baseline. (NCT01318902)
Timeframe: From the first dose of study drug plus 30 days after last dose of study drug or until the initiation of subsequent antineoplastic therapy (Up to approximately 13 months)

,,,
InterventionParticipants (Count of Participants)
ThrombocytopeniaAnaemiaNeutropeniaHyponatraemiaHypokalaemiaBlood creatinine increasedPlatelet count decreased
Dose Escalation Cohort: Ixazomib 4.0 mg2201110
Dose Escalation Cohort: Ixazomib 5.5 mg0000002
Dose Expansion Cohort: Ixazomib 4.0 mg (PI Exposed)2011110
Dose Expansion Cohort: Ixazomib 4.0 mg (PI Naive)2201000

Number of Participants With Peripheral Neuropathy Reported as a TEAE

Neurotoxicity was assessed as the number of participants with the TEAE of peripheral neuropathy. (NCT01318902)
Timeframe: From the first dose of study drug plus 30 days after last dose of study drug or until the initiation of subsequent antineoplastic therapy (Up to approximately 13 months)

,,,
InterventionParticipants (Count of Participants)
Peripheral sensory neuropathyNeuropathy peripheral
Dose Escalation Cohort: Ixazomib 4.0 mg11
Dose Escalation Cohort: Ixazomib 5.5 mg00
Dose Expansion Cohort: Ixazomib 4.0 mg (PI Exposed)10
Dose Expansion Cohort: Ixazomib 4.0 mg (PI Naive)10

TEmax: Time to Maximum Observed Effect (Emax) of Whole Blood 20S Proteasome Inhibition for Ixazomib

(NCT01318902)
Timeframe: Cycle 1: Day 1 (MTD cohort participants only, 4.0 mg) and Day 15 (all participants enrolled in the study): predose (within 1 hour (hr) before dosing), and postdose at multiple timepoints up to 168 hr

Interventionhours (Median)
Cycle 1, Day 1Cycle 1, Day 15
Ixazomib 4.0 mg1.00001.0300

Tmax: Time of First Occurrence of Cmax for Ixazomib

(NCT01318902)
Timeframe: Cycle 1: Day 1 (MTD cohort participants only, 4.0 mg) and Day 15 (all participants enrolled in the study): predose (within 1 hour (hr) before dosing), and postdose at multiple timepoints up to 168 hr

Interventionhours (Median)
Cycle 1, Day 15
Ixazomib 5.5 mg0.7500

Tmax: Time of First Occurrence of Cmax for Ixazomib

(NCT01318902)
Timeframe: Cycle 1: Day 1 (MTD cohort participants only, 4.0 mg) and Day 15 (all participants enrolled in the study): predose (within 1 hour (hr) before dosing), and postdose at multiple timepoints up to 168 hr

Interventionhours (Median)
Cycle 1, Day 1Cycle 1, Day 15
Ixazomib 4.0 mg1.00001.0000

Trials

2 trials available for glycine and Amyloidosis

ArticleYear
Phase 2 trial of ixazomib, cyclophosphamide, and dexamethasone for previously untreated light chain amyloidosis.
    Blood advances, 2022, 09-27, Volume: 6, Issue:18

    Topics: Aged; Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Bortezomib; Cycl

2022
A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis.
    Blood, 2017, 08-03, Volume: 130, Issue:5

    Topics: Administration, Oral; Aged; Amyloidosis; Boron Compounds; Disease-Free Survival; Female; Follow-Up S

2017
A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis.
    Blood, 2017, 08-03, Volume: 130, Issue:5

    Topics: Administration, Oral; Aged; Amyloidosis; Boron Compounds; Disease-Free Survival; Female; Follow-Up S

2017
A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis.
    Blood, 2017, 08-03, Volume: 130, Issue:5

    Topics: Administration, Oral; Aged; Amyloidosis; Boron Compounds; Disease-Free Survival; Female; Follow-Up S

2017
A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis.
    Blood, 2017, 08-03, Volume: 130, Issue:5

    Topics: Administration, Oral; Aged; Amyloidosis; Boron Compounds; Disease-Free Survival; Female; Follow-Up S

2017

Other Studies

11 other studies available for glycine and Amyloidosis

ArticleYear
Modulating Nanodroplet Formation En Route to Fibrillization of Amyloid Peptides with Designed Flanking Sequences.
    Biomacromolecules, 2022, Oct-10, Volume: 23, Issue:10

    Topics: Amyloid; Amyloid beta-Peptides; Amyloidosis; Glycine; Humans; Nanostructures; Serine

2022
Solution structure of 6aJL2 and 6aJL2-R24G amyloidogenics light chain proteins.
    Biochemical and biophysical research communications, 2015, Jan-09, Volume: 456, Issue:2

    Topics: Amino Acid Sequence; Amyloid; Amyloidosis; Arginine; Entropy; Glycine; Humans; Immunoglobulin lambda

2015
A new transthyretin variant Leu55Gln in a patient with systemic amyloidosis.
    Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis, 2002, Volume: 9, Issue:4

    Topics: Amyloidosis; Female; Glycine; Humans; Leucine; Middle Aged; Mutation; Polymorphism, Restriction Frag

2002
Fatal cerebral haemorrhage after liver transplantation in a patient with transthyretin variant (gly53glu) amyloidosis.
    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2006, Volume: 27, Issue:5

    Topics: Adult; Amyloidosis; Cerebral Hemorrhage; Glutamic Acid; Glycine; Humans; Liver Transplantation; Male

2006
Transthyretin Ser 6 gene frequency in individuals without amyloidosis.
    Human genetics, 1995, Volume: 95, Issue:3

    Topics: Amyloidosis; Founder Effect; Gene Frequency; Glycine; Humans; Point Mutation; Polymorphism, Genetic;

1995
Transglutaminase facilitates the formation of polymers of the beta-amyloid peptide.
    Brain research, 1994, Jul-18, Volume: 651, Issue:1-2

    Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloidosis; Glycine; Humans; Lysine; Mutation; Transgluta

1994
A Cys634Gly substitution of the RET proto-oncogene in a family with recurrence of multiple endocrine neoplasia type 2A and cutaneous lichen amyloidosis.
    Clinical genetics, 1997, Volume: 51, Issue:2

    Topics: Adolescent; Adult; Amyloidosis; Child; Cysteine; Deoxyribonucleases, Type II Site-Specific; Drosophi

1997
Is the Ala138Gly alteration of MEFV gene important for amyloidosis?
    Human mutation, 2001, Volume: 17, Issue:1

    Topics: Alanine; Amino Acid Substitution; Amyloidosis; Cytoskeletal Proteins; Familial Mediterranean Fever;

2001
[Gastroenterologic diseases and their relationship to the urogenital system].
    Zeitschrift fur Urologie und Nephrologie, 1978, Volume: 71, Issue:9

    Topics: Amyloidosis; Bile Acids and Salts; Celiac Disease; Cholelithiasis; Cholestyramine Resin; Colitis, Ul

1978
In vivo metabolism of a mutant apolipoprotein, apoA-IIowa, associated with hypoalphalipoproteinemia and hereditary systemic amyloidosis.
    Journal of lipid research, 1992, Volume: 33, Issue:5

    Topics: Adult; Amyloidosis; Apolipoprotein A-I; Arginine; Electrophoresis, Gel, Two-Dimensional; Female; Gly

1992
The structural subunit of amyloid. Isolation and characterization of a polypeptide capable of fibril formation.
    European journal of biochemistry, 1972, Jul-13, Volume: 28, Issue:2

    Topics: Amino Acids; Amyloid; Amyloidosis; Birefringence; Carbohydrates; Chromatography, Thin Layer; Congo R

1972